Semaglutide vs Tirzepatide

SURMOUNT-5 randomized 751 adults with obesity and without type 2 diabetes to weekly tirzepatide or semaglutide for seventy-two weeks. It was an open-label trial, so participants and clinicians knew which treatment was given. Tirzepatide doses were 10 or 15 mg; semaglutide doses were 1.7 or 2.4 mg, according to the maximum tolerated dose.

This is stronger comparison evidence than placing two separate placebo-controlled studies beside each other. It still does not describe every dose, everyone with diabetes, or current oral semaglutide and 7.2 mg injection options. An average advantage does not establish a better result for every individual.

Both medicines use gradual dose escalation. The instructions for missed doses, devices, and switching are different. Comparing milligram numbers does not establish equivalent strength. A change of medicine needs a new prescription plan, including the starting dose and timing.

Wegovy has cardiovascular risk-reduction indications for eligible adults with established cardiovascular disease and overweight or obesity. Its injection also has a specified MASH indication. Zepbound has an indication for moderate to severe obstructive sleep apnea in adults with obesity. Each requires the full label criteria.

For type 2 diabetes, Ozempic and Mounjaro have their own indications, dosing, and outcome evidence. The treatment decision should use the exact product and diagnosis. Coverage may follow those distinctions, so check the formulary and prior-authorization rules before switching.

Digestive effects were the most common adverse events in both SURMOUNT-5 groups, generally mild to moderate and occurring mainly during escalation. A person who cannot tolerate one medicine may need a different dose or treatment, but the trial cannot predict that response. Severe abdominal pain, repeated vomiting, or dehydration requires assessment.

Both are contraindicated with personal or family medullary thyroid carcinoma, MEN2, or serious hypersensitivity. Discuss severe gastroparesis, pancreatitis, gallbladder disease, kidney issues, diabetic eye disease, pregnancy plans, and other medicines. Semaglutide requires stopping at least two months before a planned pregnancy.

A useful decision includes the likely maintenance dose, follow-up, nutrition support, continuing cost, and what happens during a supply or coverage interruption. Avoid combining the medicines or overlapping doses without explicit prescribing instructions.